Reference number
1759-H

SPECIALTY QUANTITY LIMIT PROGRAM

NEULASTA (pegfilgrastim)
FULPHILA (pegfilgrastim-jmdp)
UDENYCA (pegfilgrastim-cbqv)
ZIEXTENZO (pegfilgrastim-bmez)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-Recommended dosing
Neulasta/Fulphila/Udenyca/ Ziextenzo (pegfilgrastim) injection 6 mg per 0.6 mL solution	2 per 28 days	Patients with cancer receiving myelosuppressive chemotherapy: • 6 mg subcutaneously once per chemotherapy cycle • Pediatric patients: Based on body weight not to exceed adult doses Patients with hematopoietic subsyndrome of Acute Radiation Syndrome: • 2 doses, 6mg each, subcutaneously one week apart.

III. REFERENCES

1. Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc.; April 2019.
2. Fulphila [package insert]. Zurich, Switzerland: Mylan; May 2019.
3. Udenyca [package insert]. Redwood City, California: Coherus BioSciences, Inc: September 2019.
4. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc.; November 2019.

CVS caremark™